Preoperative Chemotherapy for Colorectal Liver Metastases: Impact on Hepatic Histology and Postoperative Outcome

Colucci, 1994, Biochemical modulation of fluorouracil with high dose methotrexate or folinic acid in advanced colorectal cancer patients. Gruppo Oncologico dell’ Italia Meridionale (GOIM), Anticancer Res, 14, 2157

Saltz, 2000, Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group, N Engl J Med, 343, 905, 10.1056/NEJM200009283431302

Leichman, 1995, Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study, J Clin Oncol, 13, 1303, 10.1200/JCO.1995.13.6.1303

Buroker, 1994, Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer, J Clin Oncol, 12, 14, 10.1200/JCO.1994.12.1.14

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992;10:896–903.

de Gramont, 2000, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J Clin Oncol, 18, 2938, 10.1200/JCO.2000.18.16.2938

Giacchetti, 2000, Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer, J Clin Oncol, 18, 136, 10.1200/JCO.2000.18.1.136

Goldberg, 2004, A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer, J Clin Oncol, 22, 23, 10.1200/JCO.2004.09.046

Tournigand, 2004, FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study, J Clin Oncol, 22, 229, 10.1200/JCO.2004.05.113

Bismuth, 1996, Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy, Ann Surg, 224, 509, 10.1097/00000658-199610000-00009

Adam, 2004, Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival, Ann Surg, 240, 644, 10.1097/01.sla.0000141198.92114.f6

Adam, 2001, Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal, Ann Surg Oncol, 8, 347, 10.1007/s10434-001-0347-3

Parikh, 2003, Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy, J Gastrointest Surg, 7, 1082, 10.1016/j.gassur.2003.08.005

Rubbia-Brandt, 2004, Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer, Ann Oncol, 15, 460, 10.1093/annonc/mdh095

Fernandez, 2005, Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases, J Am Coll Surg, 200, 845, 10.1016/j.jamcollsurg.2005.01.024

Kooby, 2003, Impact of steatosis on perioperative outcome following hepatic resection, J Gastrointest Surg, 7, 1034, 10.1016/j.gassur.2003.09.012

Martin, 2002, Quality of complication reporting in the surgical literature, Ann Surg, 235, 803, 10.1097/00000658-200206000-00007

Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701

Adam, 2004, Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?, Ann Surg, 240, 1052, 10.1097/01.sla.0000145964.08365.01

Pawlik, 2006, Debunking dogma: surgery for four or more colorectal liver metastases is justified, J Gastrointest Surg, 10, 240, 10.1016/j.gassur.2005.07.027

Vauthey, 2006, Chemotherapy regimen predicts steatohepatitis and an increase in ninety-day mortality after resection of hepatic colorectal metastases, J Clin Oncol, 24, 2065, 10.1200/JCO.2005.05.3074

Brunt, 2004, Nonalcoholic steatohepatitis, Semin Liver Dis, 24, 3, 10.1055/s-2004-823098

Farrell, 2006, Nonalcoholic fatty liver disease: from steatosis to cirrhosis, Hepatology, 43, S99, 10.1002/hep.20973

Ratziu, 2005, Sampling variability of liver biopsy in nonalcoholic fatty liver disease, Gastroenterology, 128, 1898, 10.1053/j.gastro.2005.03.084

Bellentani, 2000, Prevalence of and risk factors for hepatic steatosis in Northern Italy, Ann Intern Med, 132, 112, 10.7326/0003-4819-132-2-200001180-00004

Angulo, 2002, Treatment of non-alcoholic steatohepatitis, Best Pract Res Clin Gastroenterol, 16, 797, 10.1053/bega.2002.0327

Clark, 2002, Nonalcoholic fatty liver disease, Gastroenterology, 122, 1649, 10.1053/gast.2002.33573

Neuschwander-Tetri, 2003, Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference, Hepatology, 37, 1202, 10.1053/jhep.2003.50193

Petersen, 2003, Mitochondrial dysfunction in the elderly: possible role in insulin resistance, Science, 300, 1140, 10.1126/science.1082889

Lowell, 2005, Mitochondrial dysfunction and type 2 diabetes, Science, 307, 384, 10.1126/science.1104343

Kim, 2001, Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance, Proc Natl Acad Sci U S A, 98, 7522, 10.1073/pnas.121164498

Friedman, 2002, Fat in all the wrong places, Nature, 415, 268, 10.1038/415268a

Browning, 2004, Molecular mediators of hepatic steatosis and liver injury, J Clin Invest, 114, 147, 10.1172/JCI200422422

Farrell, 2005, Signalling links in the liver: knitting SOCS with fat and inflammation, J Hepatol, 43, 193, 10.1016/j.jhep.2005.04.004

Behrns, 1998, Hepatic steatosis as a potential risk factor for major hepatic resection, J Gastrointest Surg, 2, 292, 10.1016/S1091-255X(98)80025-5

Belghiti, 2000, Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection, J Am Coll Surg, 191, 38, 10.1016/S1072-7515(00)00261-1